AI-powered drug company spun out of Google’s DeepMind says human trials are ‘very close’ After years of development, Isomorphic Labs says its AI-created drugs are nearly ready for human trials.

Alphabet’s Isomorphic Labs, spun out of DeepMind, is preparing to start human trials of AI-designed drugs after raising $600 million.

Google DeepMind is getting ready to begin human testing of drugs developed using artificial intelligence. All you need to know ...

A secretive, Google-backed lab is using artificial intelligence to invent new medicines for humanity's worst illnesses. But can we trust drugs designed by a mind that isn't human?

The biotechnology sector is hailing a major milestone as Isomorphic Labs, a startup incubated by Google DeepMind, prepares to enter human trials with a drug candidate designed using artificial ...

A New Era of Research with Health Studio Clinical trials are the backbone of medical advancement but they’ve historically ...

Traditionally, drug discovery relied heavily on trial and error, with long timelines and high costs. The introduction of ...

In an industry where 90 percent of drug candidates fail before reaching the market, a handful of startups are betting everything on AI to beat the odds.

While AI-driven approaches tout increased speed and lower costs, commercial interests compromise scientific collaboration.

Isomorphic Labs, a subsidiary of Alphabet Inc., is close to human trials for its AI-designed medicines. Other companies are also racing to use AI in drug discovery.